| 摘要 |
<p>The present invention relates to combination therapies for the treatment of cancer using LNA oligomers targeting Bcl-2 in conjunction with CD-20 inhibitors, such as Rituximab, or a CD20 antibody is selected from the group consisting of Ofatumumab (2F2), 11B8, 7D8, 2C6, Veltuzumab, AME-133v Ibritumomab Tiuxetan, Tositumomab, TRU-015, 2H7.vl6, Ocrelizumab, Pro131921, R7159, and GA-101.</p> |
| 申请人 |
SANTARIS PHARMA A/S;WISSENBACH, MARGIT;HANSEN, JENS BO RODE;HOEG, ANJA;MCCULLAGH, KEITH |
发明人 |
WISSENBACH, MARGIT;HANSEN, JENS BO RODE;HOEG, ANJA;MCCULLAGH, KEITH |
